Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Arecor Therapeutics's Enterprise Value is £17.00 Mil.
Arecor Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £1.01 Mil. Therefore, Arecor Therapeutics's EV-to-EBIT ratio for today is 16.92.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Arecor Therapeutics's Enterprise Value is £17.00 Mil.
Arecor Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £1.22 Mil. Therefore, Arecor Therapeutics's EV-to-EBITDA ratio for today is 13.93.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Arecor Therapeutics (LSE:AREC) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Arecor Therapeutics's current Enterprise Value is £17.00 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £1.01 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Arecor Therapeutics's current Enterprise Value is £17.00 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £1.22 Mil.
Arecor Therapeutics's current Enterprise Value is £17.00 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was £1.71 Mil.
Arecor Therapeutics's current Enterprise Value is £17.00 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was £-2.36 Mil.
Arecor Therapeutics's current Enterprise Value is £17.00 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was £-2.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arecor Therapeutics Enterprise Value Related Terms
Arecor Therapeutics Enterprise Value Historical Data
* Premium members only.
The historical data trend for Arecor Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:AREC vs VRTX, REGN, RVMD: Enterprise Value Comparison
For the Biotechnology subindustry, Arecor Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Arecor Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arecor Therapeutics (LSE:AREC) has a Enterprise Value of £17.00 Mil as of Aug. 01, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Arecor Therapeutics and its competitors.
Is Arecor Therapeutics' Enterprise Value too high?
Arecor Therapeutics' current Enterprise Value is £17.00 Mil. Overall, Arecor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Enterprise Value compare to VRTX and REGN?
Arecor Therapeutics' Enterprise Value of £17.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Arecor Therapeutics and its competitors. Arecor Therapeutics's current Enterprise Value is £17.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Arecor Therapeutics (LSE:AREC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.44, compared to a current price of £0.61 — trading 38.6% above its estimated fair value. The current Enterprise Value is £17.00 Mil. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Arecor Therapeutics (LSE:AREC), the current Enterprise Value is £17.00 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arecor Therapeutics (LSE:AREC) Overvalued in 2026?
Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued.
The current stock price of £0.61 is trading 38.6% above its estimated GF Value™ of £0.44.
GuruFocus considers Arecor Therapeutics to be Significantly Overvalued.
Key valuation signals for LSE:AREC:
Enterprise Value: £17.00 Mil
GF Value™: £0.44 vs. price of £0.61 (38.6% above fair value)
No single metric tells the full story. See the LSE:AREC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score
Get the complete analysis for LSE:AREC
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AREC has been successfully added to your 
